Transmedics Group Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Well, good morning, and welcome to Day 4 of the Morgan Stanley Healthcare Conference 2020. My name is David Lewis, medical device analyst at Morgan Stanley. We appreciate your attendance throughout these last four days. We've got another very exciting day here on Day 4, really focusing on some mid-cap emerging technology companies, and I'm delighted to have with us here to start the day, one of those -- such companies, TransMedics. We've got their CEO, Waleed Hassanein; and Stephen Gordon, their CFO. We're going to dispense with the preamble. We're going to get straight into Q&A.
Questions & Answers
And now, Waleed, it's interesting. Transplantation is a bit of a -- every company has reacted to COVID recovery differently. I think initially, people said, "Hey, transplantation is something that cannot be deferred, but yet these patients are immunocompromised. So COVID has impacted your business in particularly unique ways." Help us
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
